Arrowhead Pharmaceuticals (ARWR) Profit After Tax (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Profit After Tax data on file, last reported at -$139.1 million in Q1 2026.

• Quarterly Profit After Tax fell 137.52% year-over-year to -$139.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$274.0 million (down 72.07% YoY) and the FY2025 annual result came in at $30.1 million, up 104.94% from the prior year.
• Profit After Tax slipped to -$139.1 million in Q1 2026, from $28.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $370.7 million in Q1 2025 to a low of -$180.7 million in Q3 2024.
• A 5-year average of -$59.9 million and a median of -$104.1 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax plunged 366.37% — and 2025, when it jumped 391.9%.
• Tracing ARWR's Profit After Tax over 5 years: stood at -$41.8 million in 2022, then slumped by 223.78% to -$135.4 million in 2023, then decreased by 29.43% to -$175.2 million in 2024, then jumped by 116.12% to $28.2 million in 2025, then tumbled by 592.5% to -$139.1 million in 2026.
• The last three Profit After Tax figures came in at -$139.1 million (Q1 2026), $28.2 million (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.